Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis

Pharmaceutical Statistics

Volumn 13, Issue 1, 2014, Pages 55-70

  Ohlssen, David ^a   Price, Karen L ^b   Amy Xia, H ^c   Hong, Hwanhee ^d   Kerman, Jouni ^a   Fu, Haoda ^b   Quartey, George ^e   Heilmann, Cory R ^b   Ma, Haijun ^c   Carlin, Bradley P ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ELI LILLY AND COMPANY   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e GENENTECH INC   (United States)

Author keywords

drug safety meta analysis; mixed treatment comparisons; multiple outcomes; network meta analysis; prior sensitivity; rare events; reporting Bayesian analysis

Indexed keywords

CELECOXIB; DICLOFENAC; ETORICOXIB; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTICLE; BAYES THEOREM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; MATHEMATICAL COMPUTING; MATHEMATICAL PARAMETERS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PROCESS DEVELOPMENT; RANDOM SAMPLE; STATISTICAL DISTRIBUTION; TREATMENT INDICATION; CHEMICALLY INDUCED DISORDER; DRUG DEVELOPMENT; DRUG SAFETY META-ANALYSIS; HUMAN; META ANALYSIS (TOPIC); MIXED TREATMENT COMPARISONS; MULTIPLE OUTCOMES; NETWORK META-ANALYSIS; PRIOR SENSITIVITY; RARE EVENTS; REPORTING BAYESIAN ANALYSIS;

DRUG SAFETY META-ANALYSIS; MIXED TREATMENT COMPARISONS; MULTIPLE OUTCOMES; NETWORK META-ANALYSIS; PRIOR SENSITIVITY; RARE EVENTS; REPORTING BAYESIAN ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BAYES THEOREM; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; HUMANS; META-ANALYSIS AS TOPIC;

EID: 84908173837     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1592     Document Type: Article

References (78)

1. Huque M,. Experiences with meta-analysis in NDA submissions. Proceedings of the Biopharmaceutical Section American Statistical Association 1988; 2: 28-33.
2. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe P, Egger M,. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet 2004; 364 (9450): 2021-2029. DOI: 10.1016/S0140-6736(04)17514-4.
3. Nissen SE, Wolski K,. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007; 356 (24): 2457-2471. DOI: 10.1056/NEJMoa072761.
4. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P, Egger M, Jüni P,. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (Clinical research edition) 2011; 342: c7086.
5. Lumley T,. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002; 21 (16): 2313-2324.
6. Lu G, Ades A,. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; 23 (20): 3105-3124.
7. Dias S, Welton N, Sutton A, Ades A,. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials 2011. Available at: http://www.nicedsu.org.uk (accessed09.27.2012).
8. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A,. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value in Health 2011; 14 (4): 429-437.
9. Carlin B, Louis T,. Bayesian methods for data analysis, 3rd ed. Chapman and Hall / CRC Press: Boca Raton, FL, 2009.
10. Spiegelhalter DJ, Abrams KR, Myles JP,. Bayesian approaches to clinical trials and health-care evaluation. Wiley: Chichester, 2004.
11. Senn S,. The many modes of meta. Drug Information Journal 2000; 34 (2): 535-549.
12. Spiegelhalter D, Best N, Carlin B, van der Linde A,. Bayesian measures of model complexity and fit (with discussion). Journal of the Royal Statistical Society Series B 2002; 64: 1-34.
13. Gelfand A, Ghosh S,. Model choice: a minimum posterior predictive loss approach. Biometrika 1998; 85: 1-11.
14. Raftery A, Madigan D, Hoeting J,. Bayesian model averaging for linear regression models. Journal of the American Statistical Association 1997; 92: 179-191.
15. Carlin J,. Meta-analysis for 2 × 2 tables: a Bayesian approach. Statistics in Medicine 1992; 11 (2): 141-158. DOI: 10.1002/sim.4780110202.
16. Smith TC, Spiegelhalter DJ, Thomas A,. Bayesian approaches to random-effects meta-analysis: a comparative study. Statistics in Medicine 1995; 14 (24): 2685-2699. DOI: 10.1002/sim.4780142408.
17. Higgins J, Thompson S, Spiegelhalter D,. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2009; 172 (1): 137-159. DOI: 10.1111/j.1467-985X.2008.00552.x.
18. Sutton A, Abrams K,. Bayesian methods in meta-analysis and evidence synthesis. Statistical Methods in Medical Research 2001; 10 (4): 277-303. DOI: 10.1177/096228020101000404.
19. Warn D, Thompson S, Spiegelhalter D,. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Statistics in Medicine 2002; 21 (11): 1601-1623. DOI: 10.1002/sim.1189.
20. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR,. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Statistics in Medicine 2005; 24 (15): 2401-2428. DOI: 10.1002/sim.2112.
21. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP,. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. International journal of epidemiology 2012; 41 (3): 818-827.
22. Sutton A, Kendrick D, Coupland C,. Meta-analysis of individual-and aggregate-level data. Statistics in Medicine 2008; 27 (5): 651-669. DOI: 10.1002/sim.2916.
23. Turner R, Spiegelhalter D, Smith G, Thompson S,. Bias modelling in evidence synthesis. Journal of the Royal Statistical Society: Series A(Statistics in Society) 2009; 172: 21-47.
24. Lee K, Thompson S,. Flexible parametric models for random-effects distributions. Statistics in Medicine 2007; 27 (3): 418-434.
25. Muthukumarana S, Tiwari RC,. Meta-analysis using Dirichlet process. Statistical Methods in Medical Research 2012. DOI: 10.1177/0962280212453891. (in press).
26. Jones HE, Ohlssen DI, Neuenschwander B, Racine A, Branson M,. Bayesian models for subgroup analysis in clinical trials. Clinical Trials 2011; 8 (2): 129-143. DOI: 10.1177/1740774510396933.
27. Browne W, Draper D,. A comparison of Bayesian and likelihood-based methods for fitting multilevel models. Bayesian Analysis 2006; 1 (3): 473-514.
28. Daniels M, Hughes M,. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16 (17): 1965-1982.
29. Berry SM, Berry DA,. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics 2004; 60 (2): 418-426. DOI: 10.1111/j.0006-341X.2004.00186.x. PMID: 15180667.
30. Dumouchel W,. Multivariate Bayesian logistic regression for analysis of clinical study safety issues. Statistical Science 2012; 27 (3): 319-339. DOI: 10.1214/11-STS381.
31. Mavridis D, Salanti G,. A practical introduction to multivariate meta-analysis. Statistical Methods in Medical Research 2012. DOI: 10.1177/0962280211432219.
32. Lu G, Ades A,. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006; 101 (474): 447-459.
33. Lu G, Ades A,. Modeling between-trial variance structure in mixed treatment comparisons. Biostatistics 2009; 10 (4): 792-805.
34. Whitehead A, Whitehead J,. A general parametric approach to the meta-analysis of randomized clinical trials. Statistics in Medicine 1991; 10 (11): 1665-1677. DOI: 10.1002/sim.4780101105.
35. Sweeting MJ, Sutton AJ, Lambert PC,. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004; 23 (9): 1351-1375. DOI: 10.1002/sim.1761.
36. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR,. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007; 26 (1): 53-77. DOI: 10.1002/sim.2528.
37. Jones B, Roger J, Lane P, Lawton A, Fletcher C, Cappelleri J, Tate H, Moneuse P,. Statistical approaches for conducting network meta-analysis in drug development. Pharmaceutical Statistics 2011; 10 (6): 523-531.
38. Van Houwelingen HC, Zwinderman KH, Stijnen T,. A bivariate approach to meta-analysis. Statistics in Medicine 1993; 12 (24): 2273-2284. DOI: 10.1002/sim.4780122405.
39. Piepho HP, Williams ER, Madden LV,. The use of two-way linear mixed models in multitreatment meta-analysis. Biometrics 2012; 68 (4): 1269-1277. DOI: 10.1111/j.1541-0420.2012.01786.x. (in press).
40. Gelman A,. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper). Bayesian Analysis 2006; 1 (3): 515-534. DOI: 10.1214/06-BA117A.
41. Salanti G, Higgins J, Ades A, Ioannidis J,. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008; 17 (3): 279-301.
42. Hong H, Carlin B, Shamliyan T, Wyman J, Ramakrishnan R, Sainfort F, Kane R,. Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons. Medical Decision Making 2013; 33 (5): 702-714.
43. Dias S, Welton N, Sutton A, Ades A,. NICE DSU technical support document 5: evidence synthesis in the baseline natural history model, 2011. Available at: http://www.nicedsu.org.uk (accessed09.27.2012).
44. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ,. Summarizing historical information on controls in clinical trials. Clinical Trials 2010; 7 (1): 5-18.
45. O' Hagan A, Buck CE, Daneshkhah A, Eiser JE, Garthwaite PH, Jenkinson DJ, Oakley JE, Rakow T,. Uncertain judgements: eliciting expert probabilities. Wiley: Chichester, 2006.
46. Oakley JE, OHagan A,. SHELF: the Sheffield elicitation framework (version 2.0), 2010. Available at: http://www.jeremy-oakley.staff.shef.ac.uk/ (accessed 04.17.2012).
47. Kinnersley N, Day S,. Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study. Pharmaceutical statistics 2013; 12 (2): 104-113. DOI: 10.1002/pst.1552.
48. Little R, Rubin D,. Statistical analysis with missing data, 2nd. Wiley: New York, 2002.
49. Hong H, Chu H, Zhang J, Carlin B,. A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons. Technical Report 2012-018, Division of Biostatistics, University of Minnesota, 2012.
50. Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339 (jul21 1): b2535-b2535. DOI: 10.1136/bmj.b2535.
51. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009; 62 (10): 1006-1012. DOI: 10.1016/j.jclinepi.2009.06.005.
52. Higgins JPT, Green S, (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org/ (accessed 09.27.2012).
53. Ades A, Caldwell D, Reken S, Welton N, Sutton A, Dias S,. NICE DSU technical support document 7: evidence synthesis of treatment efficacy in decision making: a reviewers checklist, 2012. Available at: http://www.nicedsu.org.uk (accessed09.27.2012).
54. Lang T, Secic M,. Considering prior probabilities: reporting Bayesian statistical analyses. How to report statistics in medicine. American College of Physicians: Philadelphia, USA, 1997; 231-235.
55. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA,. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. Journal of Clinical Epidemiology 2005; 58 (3): 261-268. DOI: 10.1016/j.jclinepi.2004.08.010.
56. Moher D, Schulz K, Altman D,. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Medical Research Methodology 2001; 1 (1): 1-7. DOI: 10.1186/1471-2288-1-2.
57. McGettigan P, Henry D,. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. Journal of the American Medical Association 2006; 296 (13): 1633-1644. DOI: 10.1001/jama.296.13.jrv60011. PMID: 16968831.
58. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA,. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 2005; 352 (11): 1092-1102. DOI: 10.1056/NEJMoa050493.
59. Solomon DH, Glynn RJ, Levin R, Avorn J,. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Archives of Internal Medicine 2002; 162 (10): 1099-1104.
60. Whelton A, White WB, Bello AE, Puma JA, Fort JG,. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > o= 65 years of age with systemic hypertension and osteoarthritis. The American Journal of Cardiology 2002; 90 (9): 959-963.
61. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR,. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360 (9339): 1071-1073. DOI: 10.1016/S0140-6736(02)11131-7. PMID: 12383990.
62. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A,. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of Internal Medicine 2003; 163 (4): 481-486. DOI: 10.1001/archinte.163.4.481.
63. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA,. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363 (9423): 1751-1756. DOI: 10.1016/S0140-6736(04)16299-5. PMID: 15172772.
64. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA,. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. The Lancet 2005; 365 (9458): 475-481. DOI: 10.1016/S0140-6736(05)17864-7.
65. McGettigan P, Henry D,. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Medicine 2011; 8 (9): 1-18. DOI: 10.1371/journal.pmed.1001098.
66. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenboom M, Perez-Gutthann S,. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiology and Drug Safety 2011; 20 (12): 1225-1236. DOI: 10.1002/pds.2227.
67. Lunn D, Thomas A, Best N, Spiegelhalter D,. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10 (4): 325-337.
68. Fu H, Price K, Nilsson M, Ruberg S,. Adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison. Journal of Biopharmaceutical Statistics 2013; 23 (1): 26-42.
69. Lyman G, Kuderer N,. The strengths and limitations of meta-analyses based on aggregate data. BMC Medical Research Methodology 2005; 5 (1): 1-7.
70. Berlin JA, Crowe BJ, Whalen E, Xia HA, Koro CE, Kuebler J,. Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions. Clinical Trials 2013; 10 (1): 20-31. DOI: 10.1177/1740774512465495.
71. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid C, Symmons D,. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiology and Drug Safety 2011; 20 (2): 119-130. DOI: 10.1002/pds.2046.
72. Dias S, Welton N, Caldwell D, Ades A,. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010; 29: 932-944. DOI: 10.1002/sim.3767.
73. Presanis A, Ohlssen D, Spiegelhalter D, DeAngelis D,. Conflict diagnostics in directed acyclic graphs, with applications in Bayesian evidence synthesis. Statistical Science 2013. (in press).
74. Campbell G,. Bayesian statistics in medical devices: innovation sparked by the FDA. Journal of Biopharmaceutical statistics 2011; 21 (5): 871-887. DOI: 10.1080/10543406.2011.589638.
75. Bonangelino P, Irony T, Liang S, Li X, Mukhi V, Ruan S, Xu Y, Yang X, Wang C,. Bayesian approaches in medical device clinicaltrials: a discussion with examples in the regulatory setting. Journal of Biopharmaceutical Statistics 2011; 21 (5): 938-953. DOI: 10.1080/10543406.2011.589650.
76. Price KL, Xia HA, Lakshminarayanan M, Madigan D, Manner D, Scott J, Stamey J, Thompson L,. Bayesian methods for design and analysis of safety trials. Pharmaceutical Statistics 2014; 13 (1): 13-24.
77. Xia A, Ma H, Carlin BP,. Bayesian hierarchical modeling for detecting safety signals in clinical trials. Journal of Biopharmaceutical Statistics 2011; 21 (5): 1006-1029. DOI: 10.1080/10543406.2010.520181.
78. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008.